Jubilant Pharmova reported a 17% year-on-year rise in net profit at ₹120.3 crore for the September quarter, supported by strong growth across its Radiopharma and Contract Development and Manufacturing Organisation (CDMO) businesses.

Growth was led by Radiopharma, up 16%, and the CDMO and Allergy Immunotherapy segments.

Revenue for the quarter rose 12.2% to ₹1,966.4 crore, up from ₹1,752.3 crore a year ago, driven in part by incremental revenue from the company’s new third line in the CDMO Sterile Injectables business.

EBITDA increased 18% to ₹341.4 crore, versus ₹290 crore in the year-ago period, while operating margins improved to 17.4% from 16.5%.

Radiopharma continued to see robust demand, led by increased Ruby-Fill® installations, while the Allergy Immunotherapy segment benefited

See Full Page